Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Antengene’s Anti-CD24 Antibody ATG-031 Gets Green Light for Phase I Study at MD Anderson

Fineline Cube Sep 22, 2023

Antengene Corporation Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that the Institutional Review...

Company Deals

Inmagene Biopharmaceuticals and Aditum Bio Launch JV Celexor Bio to Target Autoimmune Diseases

Fineline Cube Sep 22, 2023

Inmagene Biopharmaceuticals, a China-based biopharmaceutical company, has announced a strategic collaboration with US firm Aditum...

Company Drug

Mabwell Bioscience’s 9MW3011 Earns US FDA Fast Track Designation for Polycythemia Vera Treatment

Fineline Cube Sep 22, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...

Company Medical Device

Sansure Biotech Secures CE Mark for 60 Molecular Diagnostic Products, Including Procalcitonin Assay Kit

Fineline Cube Sep 22, 2023

Sansure Biotech Inc., a leading molecular diagnostics specialist based in China (SHA: 688289), has announced...

Company Deals

Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement

Fineline Cube Sep 21, 2023

Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm...

Company Deals

Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery

Fineline Cube Sep 21, 2023

German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...

Company Drug

Novartis’s Aimovig Approved by China’s NMPA for Preventive Migraines Treatment

Fineline Cube Sep 21, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received market approval from...

Company Drug

Organon’s Liptruzet Approved in China for Hypercholesterolemia Treatment

Fineline Cube Sep 21, 2023

US-based Organon (NYSE: OGN) has announced that it has received market approval from the National...

Company

WuXi XDC Expands Manufacturing Capacity with New GMP Facilities in Wuxi

Fineline Cube Sep 21, 2023

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Policy / Regulatory

CDE Releases 74th Batch of Generic Reference Preparations with 58 New Specifications

Fineline Cube Sep 21, 2023

The Center for Drug Evaluation (CDE) has released the 74th batch of chemical generic reference...

Company Deals

Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy

Fineline Cube Sep 21, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based...

Company Deals

Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline

Fineline Cube Sep 21, 2023

Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its...

Company Drug

Hainan Poly Pharm Submits DMF for Tecovirimat API to US FDA

Fineline Cube Sep 21, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced the filing of a Drug...

Company Legal / IP

South Africa’s Competition Commission Investigates J&J for MDR-TB Drug Pricing and Evergreening

Fineline Cube Sep 21, 2023

The Competition Commission of South Africa has announced an investigation into Johnson & Johnson (J&J;...

Company Drug

Tonghua Golden-Horse’s Octohydroaminoacridine Succinate Meets Phase III Endpoints in Alzheimer’s Disease

Fineline Cube Sep 21, 2023

China-based Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) has announced positive results from its...

Policy / Regulatory

China’s NHC Expands Rare Disease List, Includes 21 Cancer Types

Fineline Cube Sep 21, 2023

The National Health Commission (NHC) of China has released an updated national list of rare...

Company Drug

AIM Vaccine’s Serum-Free Rabies Vaccine Completes Phase III Safety Observation

Fineline Cube Sep 21, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the successful completion of the 7-day...

Company Drug Medical Device

Jiangsu Yahong’s Cevira Meets Primary Endpoint in Phase III Cervical HSIL Study

Fineline Cube Sep 21, 2023

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, has...

Company Drug

Hybio Pharmaceutical Gets NMPA Approval for COVID-19 Nasal Spray HY3000

Fineline Cube Sep 21, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has received approval from the National Medical Products...

Company Drug

GSK’s Ojjaara Approved by FDA for Anemic Myelofibrosis Patients

Fineline Cube Sep 20, 2023

The US Food and Drug Administration (FDA) has granted regulatory approval to GlaxoSmithKline (GSK; NYSE:...

Posts pagination

1 … 464 465 466 … 661

Recent updates

  • Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer
  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
  • BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
  • Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.